Another candidate for future asthma therapeutics is amlitelimab, which has already shown promising data as an OX40 ligand inhibitor in the indication of atopic dermatitis and is now in a phase II trial for bronchial asthma [183]. The gene discussed is TNFSF4; the disease is atopic eczema.